Form 4: Intellia Therapeutics Officer Sells Shares for Tax

Intellia Therapeutics' VP, Chief Accounting Officer, Michael P. Dube, sold 1,871 shares of common stock at $17.38 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Michael P. Dube, VP, Chief Accounting Officer of Intellia Therapeutics, Inc. (NTLA), reported a transaction on October 1, 2025.
• The transaction involved the disposition of 1,871 shares of Intellia Therapeutics Common Stock.
• The shares were sold at a price of $17.38 per share.
• This was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The transaction was not a volitional trade by Mr. Dube.
• Following this transaction, Mr. Dube beneficially owns 55,266 shares of Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a mandatory, non-discretionary 'sell-to-cover' for tax purposes, which is a routine event for executives and does not reflect a change in management's outlook on the company.

Positives

• The transaction was a mandatory 'sell-to-cover' for tax obligations, indicating it was not a discretionary sale based on a negative outlook by the officer.
• The transaction was pre-arranged under a Rule 10b5-1(c) plan, which is a common practice for executives to manage equity compensation and avoid accusations of trading on inside information.

Negatives

• The reporting person's direct beneficial ownership of common stock decreased by 1,871 shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transaction represents a mandatory 'sell-to-cover' for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025.
• The transaction does not represent a volitional trade by the Reporting Person.

Industry Context

Insider transactions, particularly 'sell-to-cover' sales for tax purposes upon RSU vesting, are common occurrences for executives in publicly traded companies across all industries. These transactions are typically pre-scheduled under Rule 10b5-1 plans to manage equity compensation and are generally not indicative of management's sentiment towards the company's future prospects.

Stakeholder Impact

• Shareholders: The transaction is a routine, non-discretionary sale for tax purposes and is unlikely to significantly impact shareholder perception or the company's valuation.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 details a mandatory 'sell-to-cover' transaction by an executive to satisfy tax obligations upon RSU vesting. Such transactions are routine, non-discretionary, and pre-scheduled under a 10b5-1 plan. They do not typically signal a change in the executive's confidence in the company or its future prospects. Therefore, this filing alone does not provide new information that would warrant a change from a 'hold' recommendation.

Keywords

Intellia Therapeutics, NTLA, Michael Dube, Form 4, insider transaction, stock sale, RSU vesting, tax withholding, beneficial ownership, Rule 10b5-1